Skip to main content

Table 1 Characteristics of cervical cancer patients with SCC and AC before and after matching

From: Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy

Characteristics Before matching After matching
SCC (n = 744) AC (n = 71) p SCC (n = 71) AC (n = 71) p
Age (ys)
 < 65 663 (89.1%) 64 (90.1%) 0.790 66 (93.0%) 64 (90.1%) 0.546
 ≥ 65 81 (10.9%) 7 (9.9%)   5 (7.0%) 7 (9.9%)  
FIGO stage
 Stage I 92 (12.4%) 7 (9.9%) 0.359 3 (4.2%) 7 (9.9%) 0.403
 Stage II 505 (67.9%) 54 (76.1%)   56 (78.9%) 54 (76.1%)  
 Stage III-IVA 147 (19.8%) 10 (14.1%)   12 (16.9%) 10 (14.1%)  
Primary tumour size
 < 4 cm 287 (38.6%) 29 (40.8%) 0.708 28 (39.4%) 29 (40.8%) 0.864
 ≥ 4 cm 457 (61.4%) 42 (59.2%)   43 (60.6%) 42 (59.2%)  
Para-aortic MLNs
 Yes 44 (5.9%) 10 (14.1%) 0.008 10 (14.1%) 10 (14.1%) 1.000
 No 700 (94.1%) 61 (85.9%)   61 (85.9%) 61 (85.9%)  
Pelvic MLNs
 Yes 217 (29.2%) 14 (19.7%) 0.091 14 (19.7%) 14 (19.7%) 1.000
 No 527 (70.8%) 57 (80.3%)   57 (80.3%) 57 (80.3%)  
Common iliac MLNs
 Yes 56 (7.5%) 6 (8.5%) 0.779 7 (9.9%) 6 (8.5%) 0.771
 No 688 (92.5%) 65 (91.5%)   64 (90.1%) 65 (91.5%)  
Number of pelvic MLNs
 0–3 705 (94.8%) 68 (95.8%) 0.711 65 (91.5%) 68 (95.8%) 0.491
 ≥ 4 39 (5.2%) 3 (4.2%)   6 (8.5%) 3 (4.2%)  
Concurrent chemotherapy
 Yes 613 (82.4%) 60 (84.5%) 0.654 56 (78.9%) 60 (84.5%) 0.385
 No 131 (17.6%) 11 (15.5%)   15 (21.1%) 11 (15.5%)  
  1. AC adenocarcinoma, FIGO the International Federation of Gynaecology and Obstetrics, MLNs metastatic lymph nodes, SCC squamous cell carcinoma